Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CF102
Namodenoson · 2 trials · 4 indications
Median duration of survival
Assessments of adverse events (AEs) will include characterization of type, incidence, severity (graded by CTCAE v5.0), seriousness, and relationship to treatment.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), which is a scale of functioning, from 0 (normal activity) to 5 (death)
| Arm | Type | Description |
|---|---|---|
| Namodenoson (CF102) | EXPERIMENTAL | Namodenoson 25 mg orally BID, until disease progression or unacceptable adverse events |
| Placebo | PLACEBO_COMPARATOR | Matching placebo orally BID, until disease progression or unacceptable adverse events |
| Namodenoson 25 mg | EXPERIMENTAL | namodenoson capsule, 25 mg, administered orally, twice daily for consecutive 28-day cycles |
| Name | Type | Description |
|---|---|---|
| Namodenoson | DRUG | Adenosine A3 Receptor (A3AR) agonist |
| Placebo | DRUG | Control arm |
| Namodenoson 25mg | DRUG | oral capsule |
Inclusion Criteria: 1. Males and females at least 18 years of age. 2. Diagnosis of HCC: * For patients without cirrhosis at the time of diagnosis, histologic confirmation is required (archival tissue is acceptable). * For patients with underlying cirrhosis at the time of diagnosis, diagnosis...
Namodenoson is an investigational small molecule being studied for the treatment of pancreatic adenocarcinoma and hepatocellular carcinoma. It is currently in clinical development for these oncology indications.
Namodenoson targets the ADORA3 receptor, acting as an agonist. This mechanism is being investigated for its potential role in treating certain cancers.
Namodenoson is being developed by Can-Fite Biopharma Ltd, a biopharmaceutical company traded under the ticker symbol CANF.
Namodenoson is in Phase 3 clinical development for hepatocellular carcinoma. It is also being studied in a Phase 2 trial for pancreatic cancer. The drug is investigational and not yet approved.
Namodenoson is being evaluated in two clinical trials. NCT05201404 is a Phase 3 study in advanced hepatocellular carcinoma with Child-Pugh Class B7 cirrhosis, enrolling 471 participants. NCT06387342 is a Phase 2 study in advanced pancreatic cancer, enrolling 20 participants.